For more information on Nephros, please visit the Company's website at http://www.nephros.com.
Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.
Forward-looking statements are not guarantees of future performance,
are based on assumptions and are subject to various known and unknown risks
and uncertainties, many of which are beyond Nephros's control. Actual
results may differ materially from the expectations contained in the
forward-looking statements. Factors that may cause such differences include
the risks that Nephros may not be able: (i) to obtain funding if and when
needed or on favorable terms; (ii) to continue as a going concern; (iii) to
liquidate its short-term investments when needed to fund its operations;
(iv) to maintain compliance with the AMEX's continued listing standards;
(v) to demonstrate in pre-clinical or clinical trials the anticipated
efficacy, safety or cost savings of products that appeared promising to
Nephros in research or clinical trials; (vi) to obtain appropriate or
necessary governmental approvals to achieve its business plan or
effectively market its products; (vii) to have its technologies and
products accepted in current or future target markets; or (viii) to secure
or enforce adequate legal protection, including patent protection, for its
products. More detailed information about Nephros and the
|SOURCE Nephros, Inc.|
Copyright©2008 PR Newswire.
All rights reserved